» Articles » PMID: 26977169

Cholangiocarcinoma Secondary to Primary Sclerosing Cholangitis in Explanted Livers: A Single-Center Study in the South of Iran

Overview
Journal Hepat Mon
Publisher Brieflands
Specialty Gastroenterology
Date 2016 Mar 16
PMID 26977169
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Primary sclerosing cholangitis (PSC) is a chronic disease, characterized by chronic inflammation and fibrosis of bile duct epithelial cells. This is a significant contributory factor to the development of malignancy, most commonly cholangiocarcinoma (CCA), which is the second most common malignant liver tumor.

Objectives: For the first time in Iran, we intend to describe our experience with cases of PSC, with and without CCA, in explanted livers, and compare our results with those found in other areas of the world.

Patients And Methods: The study population comprised 181 individuals with a diagnosis of PSC who had undergone liver transplantation in the main liver transplant center of Iran, the largest center of hepatobiliary surgery in the south of that country, over a 3-year period between 2012 and 2014. All explanted livers, with and without CCA, were evaluated.

Results: Of the 181 patients, 16 were found to have CCA, two of whom had been diagnosed after pathologic study of the explanted livers. Therefore it appeared that 8.8% of the patients with PSC in our center had developed CCA before liver transplantation.

Conclusions: A comparison of our results with those obtained from other centers in both Western and Asian countries (which reported CCA in 3.6% - 36.5% of patients with PSC), shows that the incidence of CCA in the patients we studied is intermediate.

Citing Articles

Review of incidence and outcomes of treatment of cholangiocarcinoma in patients with primary sclerosing cholangitis.

Saffioti F, Mavroeidis V World J Gastrointest Oncol. 2021; 13(10):1336-1366.

PMID: 34721770 PMC: 8529934. DOI: 10.4251/wjgo.v13.i10.1336.


Geoepidemiologic variation in outcomes of primary sclerosing cholangitis.

Mehta T, Weissman S, Fung B, Tabibian J World J Hepatol. 2020; 12(4):116-124.

PMID: 32685104 PMC: 7336294. DOI: 10.4254/wjh.v12.i4.116.


Precursor Lesions of Cholangiocarcinoma: A Clinicopathologic Review.

Geramizadeh B Clin Pathol. 2020; 13:2632010X20925045.

PMID: 32596664 PMC: 7297471. DOI: 10.1177/2632010X20925045.


Biliary Intraepithelial Neoplasia in Non-biliary Cirrhosis-Report From 100 Explanted Livers: A Single Center Experience.

Zarei M, Shasaeefar A, Kazemi K, Dehghani M, Malekhosseini S, Geramizadeh B Clin Pathol. 2019; 12:2632010X19876934.

PMID: 31555761 PMC: 6749781. DOI: 10.1177/2632010X19876934.


Cholangiocarcinoma in Patients with Primary Sclerosing Cholangitis (PSC): a Comprehensive Review.

Song J, Li Y, Bowlus C, Yang G, Leung P, Gershwin M Clin Rev Allergy Immunol. 2019; 58(1):134-149.

PMID: 31463807 DOI: 10.1007/s12016-019-08764-7.


References
1.
Schrumpf E, Boberg K, Karlsen T . Primary sclerosing cholangitis - the Norwegian experience. Scand J Gastroenterol. 2015; 50(6):781-96. DOI: 10.3109/00365521.2015.1028996. View

2.
Singh S, Talwalkar J . Primary sclerosing cholangitis: diagnosis, prognosis, and management. Clin Gastroenterol Hepatol. 2013; 11(8):898-907. PMC: 3692584. DOI: 10.1016/j.cgh.2013.02.016. View

3.
Rosen C, Nagorney D, Wiesner R, Coffey Jr R, Larusso N . Cholangiocarcinoma complicating primary sclerosing cholangitis. Ann Surg. 1991; 213(1):21-5. PMC: 1358305. DOI: 10.1097/00000658-199101000-00004. View

4.
Singal A, Stanca C, Clark V, Dixon L, Levy C, Odin J . Natural history of small duct primary sclerosing cholangitis: a case series with review of the literature. Hepatol Int. 2011; 5(3):808-13. DOI: 10.1007/s12072-011-9260-4. View

5.
Lutz H, Trautwein C, Tischendorf J . Primary sclerosing cholangitis: diagnosis and treatment. Dtsch Arztebl Int. 2014; 110(51-52):867-74. PMC: 3928533. DOI: 10.3238/arztebl.2013.0867. View